Document is current
Any future updates will be listed below
-
Authors
Li, Xiaoyang
Dong, Yuexin
Li, Ya
Ren, Ruibao
Wu, Wen
Zhu, Hongming
Zhang, Yunxiang
Hu, Jiong
Li, Junmin https://orcid.org/0000-0002-7471-8053
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of the People’s Republic of China (81500162, 81770144, 81870110)
Clinical Research Plan of SHDC (16CR1034B)
Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research (2019CXJQ01)
Clinical Research Center, Shanghai Jiao Tong University School of Medicine (DLY201513)
- License Information
-
More Information
Article History
Received: 9 November 2018
Accepted: 23 July 2019
First Online: 20 August 2019
Ethics approval and consent to participate
: The study was approved by the Human Ethics Committee of the Ruijin Hospital and was in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients, including the patient who died during the trial.
: Not applicable.
: The authors declare that they have no competing interests.Decitabine was provided free of charge by Chiatai Tianqing Pharma (China), which played no role in the study design, data collection, analysis, or writing of the manuscript.
